Y-mAbs Therapeutics (YMAB) reported Q1 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.9 million.
Y-mAbs Therapeutics (YMAB) reported Q1 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.9 million.